Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer

Summary

RATIONALE: Marimastat may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of marimastat in treating patients who have residual stage III non-small cell lung cancer.

Timeline

Start

1996-12

Primary completion

—

Completion

2004-05

Drugs

Indications